Physician profile
Brian D Smith
NPI 1215908272
$138,655.18
in general payments reported to CMS, 2019-2025
50 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,690 · 2021: $2,688 · 2022: $2,856 · 2023: $2,790 · 2024: $4,932 · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Food and Beverage: $9,713 · Education: $93.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,697.50 |
| Food and Beverage | $9,713.16 |
| Education | $93.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $100,697.50 | 2024-2025 | Capsocam Plus, Capsocam Colon |
| Allergan, INC. | $17,536.82 | 2019-2020 | |
| Abbvie INC. | $5,268.91 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $3,191.71 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,843.98 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $1,306.55 | 2019-2025 | |
| Qol Medical, LLC | $1,258.18 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $935.43 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $546.61 | 2019-2025 | |
| Lilly USA, LLC | $522.32 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $443.90 | 2019-2025 | Suflave, Sutab |
| Celgene Corporation | $417.86 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $364.15 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $357.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $303.38 | 2019-2023 | Rebyota |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $291.98 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $282.01 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $278.71 | 2019-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $249.71 | 2019-2021 | |
| Covidien LP | $241.88 | 2019 | |
| Ardelyx, INC. | $239.18 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $210.95 | 2021-2023 | |
| Celltrion USA INC. | $197.18 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $190.73 | 2019-2024 | Ocaliva |
| Organon LLC | $182.48 | 2023-2025 | Hadlima, Renflexis |
| Redhill Biopharma INC. | $177.85 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $127.22 | 2023-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $114.26 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $104.49 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $97.99 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $97.31 | 2024-2025 | Iqirvo |
| Ucb, INC. | $69.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.22 | 2023-2024 | Cyltezo |
| Amgen INC. | $47.07 | 2022-2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $46.39 | 2024-2025 | |
| Novo Nordisk INC | $41.58 | 2021-2025 | Wegovy |
| Shire North American Group INC | $31.00 | 2019 | |
| Echosens North America, INC. | $29.79 | 2024-2025 | Fibroscan, Fibroscan |
| Alnylam Pharmaceuticals INC. | $29.57 | 2025 | Givlaari |
| Exact Sciences Corporation | $22.26 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $21.74 | 2019 | |
| Endo Pharmaceuticals INC. | $19.16 | 2019 | |
| Shionogi INC | $18.51 | 2020 | |
| Medtronic, INC. | $16.05 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.90 | 2025 | Sutab |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2024 | |
| Hologic Sales and Service, LLC | $11.63 | 2021 | |
| Myovant Sciences INC. | $11.30 | 2021 | |
| Endogastric Solutions, INC | $9.48 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.